Psoriasis classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 106: Line 106:
|}
|}


=== Subphenotypes ===
=== Classification based on subphenotypes ===
Several further subphenotypes have been named according to:
Several further subphenotypes have been named according to:
* Distribution (localized vs. widespread)
* Distribution (localized vs. widespread)

Revision as of 19:32, 7 August 2017

Psoriasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Psoriasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT scan

MRI

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Psoriasis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Psoriasis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Psoriasis classification

CDC on Psoriasis classification

Psoriasis classification in the news

Blogs on Psoriasis classification

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Psoriasis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Psoriasis can be classified according to clinical appearance, morphology, and localization. According to the International Psoriasis Council, psoriasis may be classified into four subtypes: plaque-type psoriasis, guttate psoriasis, generalized pustular psoriasis (GPP), and erythroderma. Several further subphenotypes have been named according to distribution (localized vs. widespread), anatomical localization (flexural - also called inverse, scalp, palms/soles/nail), size (large vs. small) and thickness (thick vs. thin) of plaques, onset (early vs. late), and disease activity (active vs. stable).

Classification

Classification based on clinical appearance, morphology, and localization

  • The International Psoriasis Council classifies psoriasis into four main forms, according to clinical appearance, morphology and localization:
    • Plaque-type psoriasis
    • Guttate psoriasis
    • Generalized Pustular Psoriasis (GPP)
    • Erythroderma
Type of Psoriasis Typical lesion Body Distribution Associated conditions[1][2][3][4][5][6]
Plaque-type psoriasis
  • Oval or irregularly shaped
  • Erythematous
  • Sharply demarcated
  • Raised plaques covered by silvery scales
  • Large plaques >3cm
  • Small plaques <3cm

Triggers include:

Guttate psoriasis
  • Multiple
  • Small
  • Drop-shaped
  • Scaly plaques
Generalized pustular psoriasis[7]
  • Generalized
Erythrodermic psoriasis (most severe)
  • >70 % of the body surface area

Classification based on subphenotypes

Several further subphenotypes have been named according to:

  • Distribution (localized vs. widespread)
  • Anatomical localization (flexural- also called inverse, scalp, palms/soles/nail)
  • Size (large vs. small)
  • Thickness (thick vs. thin) of plaques
  • Onset (early vs. late)
  • Disease activity (active vs. stable)

Classification based on severity

Pie chart showing the distribution of severity among people with psoriasis.

Psoriasis is usually graded as:

  • Mild (affecting less than 3% of the body)
  • Moderate (affecting 3-10% of the body)
  • Severe

Degree of severity

The degree of severity is generally based on the following factors:

  • The proportion of body surface area affected
  • Disease activity (degree of plaque redness, thickness and scaling)
  • Response to previous therapies
  • The impact of the disease on the person

Psoriasis Area Severity Index (PASI)

The Psoriasis Area Severity Index (PASI) is the most widely used measurement tool for psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score ranging between 0 (no disease) to 72 (maximal disease).[8] The PASI can be very difficult to use outside of trials, which has led to attempts to simplify the index for clinical use.[9]

Other types of psoriasis

References

  1. Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maître M, Ortonne JP, Paul C (2013). "Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies". J Eur Acad Dermatol Venereol. 27 Suppl 3: 36–46. doi:10.1111/jdv.12165. PMID 23845151.
  2. Gelfand JM, Yeung H (2012). "Metabolic syndrome in patients with psoriatic disease". J Rheumatol Suppl. 89: 24–8. doi:10.3899/jrheum.120237. PMC 3670770. PMID 22751586.
  3. Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, Nicolucci F, Tolino E, Zuber S, Soccodato V, Potenza C (2013). "Correlations between psoriasis and inflammatory bowel diseases". Biomed Res Int. 2013: 983902. doi:10.1155/2013/983902. PMC 3736484. PMID 23971052.
  4. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM (1986). "Drugs in exacerbation of psoriasis". J. Am. Acad. Dermatol. 15 (5 Pt 1): 1007–22. PMID 2878015.
  5. Tauscher AE, Fleischer AB, Phelps KC, Feldman SR (2002). "Psoriasis and pregnancy". J Cutan Med Surg. 6 (6): 561–70. doi:10.1177/120347540200600608. PMID 12362257.
  6. Boyd AS, Menter A (1989). "Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients". J. Am. Acad. Dermatol. 21 (5 Pt 1): 985–91. PMID 2530253.
  7. Baker H, Ryan TJ (1968). "Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases". Br. J. Dermatol. 80 (12): 771–93. PMID 4236712.
  8. "Psoriasis Update -Skin & Aging". Retrieved 2007-07-28.
  9. Louden BA, Pearce DJ, Lang W, Feldman SR (2004). "A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients". Dermatol. Online J. 10 (2): 7. PMID 15530297.

Template:WH Template:WS